Novartis: Cancer drugs Kisqali and Scemblix promise growth of 5% to 6% per year until 2030!

Novartis expects strong growth in the coming years due to significantly increased revenue expectations for its cancer drugs Kisqali and Scemblix. From 2025 to 2030, the Swiss pharmaceutical company anticipates an increase of 5% to 6% per year, as announced at an investor event in London. This forecast is based on the raised revenue potential of the two oncology products and specific upcoming clinical advancements. Novartis recently adjusted its strategy due to the planned acquisition of Avidity Biosciences With this, Novartis continues its mid-term...